Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

Bristol Myers Squibb (BMY) Stock Looks Below Fair Value Following A 41% Run

Drug approval Earnings report Financial outlook AI-generated analysis

πŸ“ˆ BMY shares have returned approximately 40.5% over the past three years, trading at US$62.91.

πŸ’° The company generated about $9.3 billion in free cash flow over the last twelve months.

πŸ“‰ Analysts project a revenue step-down from Eliquis starting in 2027 as major products mature.

πŸš€ New product approvals for Camzyos and ZENBEXUS are expected to support future drug-driven cash flows.

πŸ”¬ The company is developing late-stage platforms in CELMoDs, CAR-T, ADCs, Factor XI inhibition, and neuroscience.

πŸ’‘ A bullish community narrative values BMY at 21% undervalued based on successful platform conversion.

⚠️ A bearish community narrative considers BMY 121% overvalued due to the current entry price exceeding fair value filters.

πŸ“Š DCF models suggest intrinsic value is substantially above the current share price of $62.91.

Bullish Signals
  • The company has delivered a strong 40.5% share price return over the past three years, indicating market confidence in its trajectory.
  • Recent trial results for Camzyos and new product approvals for ZENBEXUS support expectations for future drug-driven cash flows.
  • A bullish analyst narrative suggests BMY is 21% undervalued if the company successfully converts late-stage platforms into commercially meaningful products.
Risk Factors
  • The projected step-down in revenue from Eliquis starting in 2027 necessitates restrained growth assumptions in valuation models.
  • A bearish community narrative argues the stock is 121% overvalued at current levels, suggesting the entry price exceeds fair value filters.
Full Analysis
Bristol-Myers Squibb (BMY) shares have appreciated approximately 40.5% over the past three years, driven by positive data for key therapies and a robust pipeline. The stock recently closed at US$62.91, prompting analysts to evaluate whether this valuation is supported by the company's long-term cash generation capabilities. A Discounted Cash Flow (DCF) analysis indicates that BMY's intrinsic value is substantially higher than its current market price of $62.91. The model projects free cash flow of roughly $9.3 billion over the last twelve months, assuming a gradual decline as legacy products like Eliquis face revenue steps starting in 2027, partially offset by new launches. Community analysts on Simply Wall St present divergent views on BMY's valuation. A bullish narrative suggests the stock is 21% undervalued if the company successfully commercializes late-stage platforms in areas such as CAR-T and ADCs while managing legacy declines. Conversely, a bearish perspective argues the stock is 121% overvalued at current levels, citing that the entry price exceeds fair value filters despite the company's clear quality. The divergence in opinion highlights a split between investors focused on BMY's growing late-stage portfolio and those concerned with the current share price relative to intrinsic value. The article concludes by noting that leadership strategy and prioritization will be critical factors in determining whether BMY can bridge the gap between its discounted cash flow estimates and market pricing.